OVER-THE-COUNTER, COMPLEMENTARY AND ALTERNATIVE AGENTS

VITAMINS AND MINERALS, HERBAL PRODUCTS, APPEARANCE AND PERFORMANCE ENHANCING SUPPLEMENTS

IN	STIs	NN	IRTIs	Pls	R	ті
 BICTEGRAVIR (Biktarvy) DOLUTEGRAVIR (Tivicay, Triumeq, Juluca) RALTEGRAVIR (Isentress) 	COBICISTAT (Stribild, Genvoya)	 DORAVIRINE (Pifeltro, Delstrigo) RILPIVIRINE (Edurant, Complera, Odefsey, Juluca) 	 EFAVIRENZ (Sustiva, Atripla) ETRAVIRINE (Intelence) NEVIRAPINE (Viramune) 	 ATAZANAVIR (Reyataz/Norvir, Evotaz) DARUNAVIR (Prezista/Norvir, Prezcobix, Symtuza) LOPINAVIR (Kaletra) 	ALAFENAMIDE, TAF (Descovy, Biktarvy, Genvoya, Odefsey, Symtuza)	

VITAMINS AND MINERALS

• Vitamin D			Potential for↓ vitamin D		
• Cations such as	↓ INSTI	Potential for \downarrow INSTI			
calcium, magnesium, iron, aluminum, zinc,	Raltegravir 600 mg HD tablets				
including supplements and multivitamins with high dose calcium, iron	Raltegravir 400 mg OK with calcium				

HERBAL PRODUCTS AND SUPPLEMENTS

• Echinacea	Potential↓ bictegravir	Potential for↓ NNRTI		
	Dolutegravir, raltegravir			

	INS	STIs	NN	RTIs	PIs	R	ті
	 BICTEGRAVIR (Biktarvy) DOLUTEGRAVIR (Tivicay, Triumeq, Juluca) RALTEGRAVIR (Isentress) 	• ELVITEGRAVIR/ COBICISTAT (Stribild, Genvoya)	 DORAVIRINE (<i>Pifeltro</i>, <i>Delstrigo</i>) RILPIVIRINE (<i>Edurant</i>, <i>Complera</i>, <i>Odefsey</i>, <i>Juluca</i>) 	 EFAVIRENZ (Sustiva, Atripla) ETRAVIRINE (Intelence) NEVIRAPINE (Viramune) 	 ATAZANAVIR (Reyataz/Norvir, Evotaz) DARUNAVIR (Prezista/Norvir, Prezcobix, Symtuza) LOPINAVIR (Kaletra) 	• TENOFOVIR ALAFENAMIDE, TAF (Descovy, Biktarvy, Genvoya, Odefsey, Symtuza)	 TENOFOVIR DISOPROXIL, TDF (Viread, Truvada, Atripla, Complera, Delstrigo, Stribild) ABACAVIR (Kivexa, Ziagen, Triumeq)
• Garlic	Potential for ↓ INSTI	Potential for \downarrow INSTI	Potential for ↓ NNRTI	Potential for ↓ NNRTI	Potential for \downarrow PI	Potential for \downarrow TAF	
• Ginkgo biloba			Potential for ↓ NNRTI	Potential for ↓ NNRTI	Always use boosted Pl		
• Grapefruit juice			Potential for ↑ rilpivirine				
Milk thistleSaw palmetto							

APPEARANCE AND PERFORMANCE ENHANCING SUPPLEMENTS (APES)

• Creatine	Potential additive 个 Scr without impacting renal function	Potential additive 个 Scr without impacting renal function	Rilpivirine: potential additive 个 Scr without impacting renal function		Potential additive 个 Scr without impacting renal function	Tenofovir DF: Potential additive nephrotoxicity (rare)
• Testosterone (oral IM, topical)		Potential for ↑ testosterone		Potential for ↓ testosterone	Potential for ↑ testosterone	

	IN	STIs	NN	IRTIs	Pls	R	ті
	 BICTEGRAVIR (Biktarvy) DOLUTEGRAVIR (Tivicay, Triumeq, Juluca) RALTEGRAVIR (Isentress) 	COBICISTAT (Stribild, Genvoya)	 DORAVIRINE (<i>Pifeltro</i>, <i>Delstrigo</i>) RILPIVIRINE (<i>Edurant</i>, <i>Complera</i>, <i>Odefsey</i>, <i>Juluca</i>) 	 EFAVIRENZ (Sustiva, Atripla) ETRAVIRINE (Intelence) NEVIRAPINE (Viramune) 	 ATAZANAVIR (Reyataz/Norvir, Evotaz) DARUNAVIR (Prezista/Norvir, Prezcobix, Symtuza) LOPINAVIR (Kaletra) 	• TENOFOVIR ALAFENAMIDE, TAF (Descovy, Biktarvy, Genvoya, Odefsey, Symtuza)	 TENOFOVIR DISOPROXIL, TDF (Viread, Truvada, Atripla, Complera, Delstrigo, Stribild) ABACAVIR (Kivexa, Ziagen, Triumeq)
Anabolic steroids • Oral: oxandrolone, stanozolol • IM: nandrolone							
Selective androgen receptor modulators • Andarine, ostarine							
Selective estrogen receptor modulators (SERMS) • Clomiphene, tamoxifen	Potential for tamoxifen to↓ bictegravir	Potential for ↑ tamoxifen, possibly ↓ elvitegravir Clomiphene OK	Potential for ↓ NNRTI Clomiphene OK	Potential for ↓ tamoxifen and possibly ↓ NNRTI Clomiphene OK	Potential for ↑ tamoxifen, possibly ↓ PI Clomiphene OK		
Aromatase inhibitors • Letrozole, anastrazole		Potential for ↑ aromatase inhibitor		Potential for ↓ aromatase inhibitor	Cobicistat-boosted Pl: Potential for ↑ aromatase inhibitor Ritonavir-boosted Pl: potential for ↑/↓ aromatase inhibitor		

Mechanism of Drug Interactions, Management and Monitoring

	Mechanism of	Main interacting ARVs	Management	Monitoring
Class	interaction			
Cation-containing products, including supplements and multivitamins	Chelation and decreased absorption Many Multivitamins including once daily and especially those designed for women with extra Calcium and iron, and those used during pregnancy, contain enough cations to lead to chelation of the integrase inhibitors and limit their absorption. This results in lowered levels of the integrase inhibitor and could result in loss of virologic suppression.	All INSTIS	 Management recommendations vary according to specific INSTI: Bictegravir: Administer bictegravir and polyvalent cations simultaneously with food, or separate by 2 hours. Dolutegravir: Administer dolutegravir: Administer dolutegravir and polyvalent cations simultaneously with food, or take dolutegravir 2 hours before or 6 hours after polyvalent cations. Elvitegravir/c : Stagger administration by at least 2 hours from mineral supplements. Raltegravir: ONLY 400 MG BID dose may be used with calcium carbonate; use with other polyvalent cations is not recommended. Do not use 600 mg HD tablet with any polyvalent cations. 	In all cases, monitor for continued viral suppression.
Echinacea	May induce CYP3A4 (mild)	Bictegravir, doravirine, rilpivirine	Potential for decreased ARV concentrations, clinical significance unclear.	Antiretroviral efficacy.
Garlic	May induce CYP3A4, Pgp	All ARVs	Avoid ingestion of large amounts of garlic (fresh, cooked or supplements)	Antiretroviral efficacy.
Ginkgo Biloba	Ginkgo may induce CYP3A4	bictegravir, unboosted atazanavir, NNRTIs,	Do not use unboosted atazanavir with Ginkgo.	Antiretroviral efficacy.

	Mechanism of	Main interacting ARVs	Management	Monitoring
Class	interaction			
			Consider elvitegravir/cobicistat,	
			dolutegravir or raltegravir instead of	
			bictegravir.	
			Avoid Ginkgo with NNRTI; switch to	
			boosted INSTI or INSTI metabolized	
			via UGT, or boosted PI.	
Grapefruit juice	May inhibit CYP3A4,	rilpivirine	Clinical significance unclear; caution	
	Pgp		may be warranted if patient is on	
			other drugs which inhibit CYP3A4	
			and/or have QT-prolonging effect	
Creatine	Creatine is metabolized	Cobicistat, ritonavir,	Increases in serum creatinine	Monitor renal function.
	to creatinine, and may	dolutegravir,	secondary to inhibition of renal	
	lead to higher serum	bictegravir, rilpvirine	tubular transporters generally occur	
	creatinine without		soon after starting these	
	necessarily impacting		antiretrovirals and remain stable	
	renal function.		thereafter. Use of creatine	
	Potential additive effect		supplements may enhance this	
	when combined with		effect. If additional significant	
	ARVs which inhibit renal		increases in serum creatinine occur	
	tubular secretion of		after patient is stable on	
	creatinine.		antiretrovirals, explore other causes	
			of potential nephrotoxicity.	
	Potential additive risk	Tenofovir disoproxil	Some cases of renal impairment	Monitor renal function.
	of renal toxicity.		after use of creatinine have been	
			reported.	
Aromatase inhibitors	Anastrazole: substrate	Protease inhibitors,	Potential for increased or decreased	Monitor for efficacy, toxicity of aromatase
(anastrozole, letrozole)	of CYP3A4, UGT	elvitegravir/cobicistat	concentrations of aromatase	inhibitors.
	Letrozole: substrate of	(inhibition of CYP3A4,	inhibitors.	
	СҮРЗА4, 2А6	ritonavir may induce		
		UGT), NNRTIs (induction		
		of CYP3A4)		
Selective estrogen	Clomiphene: no	Bictegravir,	Less interaction potential with	Efficacy/toxicity of tamoxifen.
receptor modulators	metabolism/transporter	elvitegravir/cobicistat,	clomiphene versus tamoxifen.	Antiretroviral efficacy.
	effects.	PIs, NNRTIs		

	Mechanism of	Main interacting ARVs	Management	Monitoring
Class	interaction			
	Tamoxifen: substrate		If using tamoxifen, consider using	
	and inducer of CYP3A4		an unboosted integrase inhibitor	
			with minimal CYP3A4 involvement	
	Potential for increased		such as dolutegravir or raltegravir.	
	tamoxifen with boosted			
	regimens or decreased			
	tamoxifen with enzyme			
	inducing NNRTIs.			
	Potential for decreased			
	ARV concentrations via			
	CYP3A4 induction by			
	tamoxifen.			

Legend:

No dose adjustment required.

Use combination with caution. Adjustment in drug dose or frequency or additional/more frequent monitoring may be required. May wish to consult with a pharmacist knowledgeable in HIV drug interactions.

Contraindicated/avoid combination.